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Introduction

43
Viruses have evolved to sneak through the innate and adaptive antiviral response both at 44 the cellular and whole organism levels, for survival and successful infection spreading (29, 38, 4 E3 ligase activities 154 E6 protein displays two types of E3 ligase activities according to the involvement or not of 155 the cellular E6-AP protein (FIGURE 2).
156
E6-AP dependent E3 ligase 157 On one hand, E6 binds through its N-terminus to the unimolecular E6-AP E3 ligase. E6-158 AP contains an active enzymatic HECT site which interacts with several E2 conjugating enzymes, 159 including UbcH5, UbcH6, UbcH7 and UbcH8 (see (110) for review). On the other hand, E6 160 recruits many cellular proteins as substrates for ubiquitination.
161
E6 oncoprotein promotes the degradation of p53 through its interaction with E6-AP to 162 form an E3 ubiquitin ligase complex (55, 117) (see also (110) for review). Firstly, E6 associates 163 with E6-AP, secondly, the dimeric E6/E6-AP complex binds to p53 and induces E6-AP-mediated 164 ubiquitination of p53, and thirdly, polyubiquitinated p53 is recognized and degraded by 26S 165 proteasome (see (110) for review). E6 association with E6-AP likely alters its substrate specificity 166 because E6-AP itself is unable to recognize p53 as a target for ubiquitination (117) . Conversely, 167 does E6 binding to E6-AP prevent its activity on normally E6-independent substrates ? The 168 precise scaffold of the E6/E6-AP/p53 complex is yet to be uncovered. It is proposed that a small 169 helical domain within E6-AP (L2G motif), which binds to E6, also associates with p53 (56), and 170 E6 binds to the core DNA-binding domain of p53 (44, 96) . Strikingly, the effect of E6 on p53 is 171 independent of the six C-terminal lysine residues in p53, which are critical for effective 172 ubiquitination mediated by the physiological cellular unimolecular RING-type E3 ligase Mdm2 173 (15) .
174
HPV E6 proteins also promote the E6-AP-dependent degradation of many other proteins 175 (see (37, 110) for review) that are independent of p53 degradation, including E6-AP (59) 
184
E6-AP independent E3 ligase 185 E6 is also an E3 ligase in the absence of E6-AP for several substrates including Blk, a 186 member of the Src-family of non-receptor tyrosine kinase, Bak, a human proapoptotic protein,
187
Mcm7 and two human homologues of the yeast DNA repair protein RAD23, HHR23A and 188 HHR23B. The mechanism by which E6 targets proteins for degradation in an E6-AP-independent 189 manner is presently unclear (see (5, 110) 
223
Herpes simplex virus-infected cell protein 0 (ICP0, also called vmw110) was initially 224 described as a protein found to accumulate in infected cells, but not present in the virion. It acts 225 as a promiscuous transactivating signal, since expression by transfection results in the activation 226 of numerous cellular genes (see (46) for review).
228
Gene and structure 
238
The RING domain is responsible for the recruitment of both of the cellular E2 ubiquitine 239 conjugating enzyme UbcH5a (13) and one cellular substrate, the ubiquitin-specific protease 240 enzyme USP7 (also called HAUSP) (35).
241
ICP0 is its own substrate for ubiquitination (16) . It also directly ubiquitinates USP7 in vitro 242 and in vivo, and, this activity leads to a reduction in cellular USP7 levels during HSV-1 infection 243 (35) . Conversely, USP7 stabilizes ICP0 in vitro and in vivo by protecting ICP0 from auto-244 ubiquitination (16). These reciprocal activities of the two proteins mimic the USP7-mediated 245 stability of Mdm2 (64). The outcome during productive HSV-1 infection is that the USP7-mediated 246 stabilization of ICP0 is dominant over ICP0-induced degradation of USP7 (10).
247
The ICP0 mediated ubiquitination of p53 is weak compared to that of Mdm2, the major 248 cellular E3 ubiquitin ligase which keeps the p53 in low level in uninfected cells. ICP0 binds to p53 249 by residues 241 to 594 and then promotes low levels of p53 ubiquitination in infected cells (11).
251
Other cellular proteins targeted for proteasome-mediated degradation by the ICP0- 
263
The second ubiquitin ligase domain HUL-1 within ICP0, is not a Zn-finger and is required 6 enzyme which forms a complex with skp1-skp2-F-box and promotes the degradation of cyclin D1 266 and cyclin D3 (see (25) for review). ICP0 was found to stabilize both cyclins D3 and D1, without 267 evidence for a direct interaction with cyclin D1 (121). UbcH3 strongly interacts with ICP0 20-241 268 region, which encompasses the RING domain, and moderately to ICP0 621-625 or HUL-1 269 domain (47). Only the latter domain and aspartate 199 are essential for ubiquitination and 270 degradation of UbcH3, since, in cells infected with HSV-1, ICP0 with disrupted RING domain has 271 no effect on UbcH3 degradation. Thus, N-terminus of ICP0 would indirectly contribute to the 272 ubiquitination of UbcH3 by capturing it and pushing it towards the second ligase activity site (46).
274
Cellular impact and counteraction of innate immunity 275
Owing its numerous substrates and multiple molecular partnerships, ICP0 interferes with 276 many viral and cellular functions. ICP0 with intact RING finger stimulates lytic infection and 
283
ICP0 is clearly involved in the dampening of the (i) development of antiviral state and (ii) 284 the amplification through the IFN IFNAR pathway.
285
(i) During infection by HSV-1, there is little expression of interferon stimulated genes 286 (ISGs), whereas cells infected by mutant ICP0 null HSV-1 exhibit high level of ISG expression (32).
287
A significant part of this ISG expression is likely independent from the elicited IFN response since 288 it is insensitive to a protein synthesis inhibitor (82, 87, 99) . ICP0 acts by inhibiting IRF-3-mediated 289 activation of ISGs (69, 81). This inhibition critically relies on intact RING domain and active 290 proteasome-dependent proteolysis (32, 69). IRF-3 turn-over is increased and nuclear 291 accumulation of IRF-3 is blocked by ICP0 (81), but ICP0 does not induce the degradation of 292 TBK1, IRF-3, IRF-7, or CBP which all belong to the IRF-3 signalling pathway (69).
293
(ii) While wild type HSC-1 is relatively insensitive to exogenous interferon α/β treatment 294 of host cells, the growth of ICP0 null HSV-1 is inhibited in Vero cells pretreated by type I interferon 295 (49, 83, 84) . Moreover, mutant ICP0 null HSV-1 poorly replicates in mice, a phenotype which is 296 reverted in IFNAR -/mice (63).
297
How does E3 ubiquitin ligase activity of ICP0 can contribute or even be responsible for 298 the ICP0 blocks of the induction of an antiviral state ?
299
(1) The ICP0 mediates the degradation of PML which is required for the interferon response.
300
Indeed, exogenous IFN does not induce an efficient antiviral state in PML -/cells and does not 301 affect the growth of ICP0 null HSV-1 in these cells (19) . Interestingly, CBP/p300, which are 302 subunits of the enhanceosome downstream to the IRF-3 pathway, bind to PML (106) and their 303 nuclear distribution is strongly modified in HSV-1 infected cells provided that ICP0 with an intact 304 RING domains is expressed (69).
305
(2) DNA-PK stabilizes IRF-3 (60), and ICP0-mediated targeting of DNA-PK for degradation may 306 contribute to the weakening the IRF-3 activation pathway.
307
(3) P53 is up-regulated by IFN to mediate apoptotic signal (97). ICP0 mediated targeting for 308 degradation of p53 can contribute to the resistance of HSV to IFN.
309
In conclusion, ICP0 is an E3 Ubiquitin ligase which targets several cellular proteins, some 310 of them being involved in the cellular innate immunity. We propose that the potent anti-innate 311 immunity properties of ICP0 results from the coordinate disruption of several innate immunity 312 pathways. Furthermore, at a late stage of HSV-1 infection, ICP0 prevents the degradation of 313 rRNA according to a new antiviral mechanism distinct from the IFN-induced RNAse L pathway. 358 E4orf6 can interact with p53 and inhibit its transactivating activity (18, 28) . In the absence 359 of E4orf6, E1B55K dramatically increases the concentration of p53 (79). But p53 transactivating 360 activity is blocked. Possibly, upon interaction with p53, E1B55K bring a repression domain close 361 to the p53 activating domain (8). E1B5K also inhibits the acetylation of p53 by PCAF and thus 362 contributes to p53 inhibition by another mechanism (73).
364
Cellular impact and counteraction of innate immunity 365
Adenoviruses have developed several genes to control the antiviral effect of innate The viral infectivity factor VIF encoded by HIV-1 and most other lentivirus was initially 375 found in the nineties to be required for replication in "non permissive" cells such as primary T cells 8 the cellular target APOBEC3G was identified (see (104) for review).
379
Gene and structure 380 VIF is coded within the region on an alternative codon frame and has a size of about 23 381 kDa. Functionally, VIF shared many features with the adenoviral E4orf4 protein. 397 Surprisingly, APOBEC3G is also monoubiquitinated by the unimolecular HECT-type E3 398 ligase Nedd4.1, for its efficient packaging within budding virions (30). Thus, APOBEC3G is the 399 substrate for both monoubiquitination and polyubiquitination by two separate E3 ligases.
400
Besides targeting APOBEC3G for ubiquitination and degradation, VIF may also directly 401 inhibit its deaminase activity, as suggested in experiments performed in E. Coli (108). Rubulavirus are enveloped RNA viruses whose replication occurs entirely within the 416 cytosol. Their genome code for less than ten proteins, nevertheless because they also have to 417 cope with the cellular innate immunity, at least one of them, V protein, is a potent inhibitor of the 
403
Cellular impact and counteraction of innate immunity
459
The functional impact of STAT3 degradation by mumps V protein remains to be clarified 460 since the role of STAT3 is variable according to the cell type (113).
462 463
Conclusion
465
We have illustrated, in this review, the various strategies used by viruses to hijack the 
471
This short survey has brought a glimpse of what we predict will be an increasing area of 
